SPONDYLOARTHROPATHIES: Apremilast: welcome advance in treatment of psoriatic arthritis

    loading  Checking for direct PDF access through Ovid

Abstract

The FDA has given approval for the use of apremilast in adults with active psoriatic arthritis—welcome news for patients and the rheumatology community. This commentary reviews some of the evidence for the use of apremilast and suggests some direction for future research.

Related Topics

    loading  Loading Related Articles